drugset / Trial / NCT04129151
Palbociclib + Ganitumab In Ewing Sarcoma
Phase 2
Terminated
10 enrolled
Dana-Farber Cancer Institute
1 Million 4 Anna Foundation · collabAlan B. Slifka Foundation · collabCarson Sarcoma Foundation · collabChemoWarrior: the eli sidler foundation · collabRutledge Cancer Foundation · collabTeaming up to Fight Childhood Cancer · collabi-ROK Foundation · collab
NaSingle-groupOpen-labelTreatment
Summary
This research study is designed to study the combination of two drugs, palbociclib and ganitumab, as a potential treatment for Ewing sarcoma. The names of the study drugs involved in this study are: * Palbociclib * Ganitumab
Timeline
- Start
- 2019-12-05
- Primary completion
- 2022-12-15
- Completion
- 2022-12-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ganitumab | Monoclonal antibody | 18 mg/kg | Intravenous |
| Subject | Palbociclib | Small molecule | 100 mg | Oral |
| Subject | Palbociclib | Small molecule | 125 mg | Oral |